Additional Study Information: The purpose of the study is to test how effective and safe the study drug SGI-110 is compared with current standard treatment for AML. The study drug, SGI-110, is changed in the body into a compound called decitabine. Decitabine is an approved drug in the US for treatment of patients with myelodysplastic syndrome (MDS) and in Europe for treatment of patients with acute myeloid leukemia (AML). Decitabine may block the growth of cancer cells. The study drug SGI-110 may have effects that differ from decitabine. The study drug SGI-110 will be given by a subcutaneous injection (under the skin).